This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Neurology  • Dementias  • Drug Therapy, Other  • Alert me on articles by topic

Does Duration of Use Matter?

Kristine Yaffe, MD

Arch Intern Med. 2007;167(20):2167-2168.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The growing interest in primary prevention of cognitive impairment and dementia has been sparked by several promising interventions, most of which have not been confirmed by recently conducted randomized clinical trials. Many observational studies, but not all, have suggested that antioxidant supplements, including beta carotene, or a diet with high intake of antioxidants reduce the risk of developing Alzheimer disease (AD) or other forms of cognitive impairment. These results, along with those from an Alzheimer Disease Cooperative Study (ADCS) trial published in 1997,¹ which showed a benefit of vitamin E treatment (2000 IU/d) for 2 years in reducing progression of AD,have sparked interest in antioxidants for treatment or prevention of cognitive disorders.

In this issue of the Archives, Grodstein and colleagues² report the results from the Physicians' Health Study II (PHSII) cognitive ancillary study. The PHSII is a randomized trial of beta carotene (a provitamin A . . . [Full Text of this Article]

AUTHOR INFORMATION

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Can Beta Carotene Supplementation Prevent Cognitive Decline?
JWatch General 2007;2007:4-4.
FULL TEXT